AMAG Pharmaceuticals (AMAG) Stock Rating Lowered by BidaskClub

BidaskClub lowered shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from a hold rating to a sell rating in a report published on Tuesday morning.

AMAG has been the topic of a number of other reports. Deutsche Bank set a $23.00 price target on shares of AMAG Pharmaceuticals and gave the company a hold rating in a research report on Thursday, September 20th. Zacks Investment Research lowered shares of AMAG Pharmaceuticals from a hold rating to a strong sell rating in a research report on Friday, October 5th. B. Riley boosted their price target on shares of AMAG Pharmaceuticals from $30.00 to $31.00 and gave the company a buy rating in a research report on Monday, August 6th. Cantor Fitzgerald set a $18.00 price target on shares of AMAG Pharmaceuticals and gave the company a hold rating in a research report on Wednesday, September 26th. Finally, Jefferies Financial Group restated a hold rating and issued a $22.00 price target on shares of AMAG Pharmaceuticals in a research report on Friday, August 3rd. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. AMAG Pharmaceuticals currently has an average rating of Hold and a consensus price target of $21.97.

NASDAQ:AMAG opened at $17.84 on Tuesday. The stock has a market capitalization of $606.79 million, a price-to-earnings ratio of -3.12 and a beta of 0.23. AMAG Pharmaceuticals has a 12 month low of $11.95 and a 12 month high of $26.10. The company has a current ratio of 2.86, a quick ratio of 2.72 and a debt-to-equity ratio of 0.34.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.88) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($1.11). The firm had revenue of $122.20 million during the quarter, compared to analyst estimates of $118.23 million. AMAG Pharmaceuticals had a negative net margin of 6.98% and a negative return on equity of 13.65%. AMAG Pharmaceuticals’s quarterly revenue was down 1.7% on a year-over-year basis. During the same quarter last year, the firm earned ($4.31) earnings per share. Research analysts predict that AMAG Pharmaceuticals will post -2.85 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. State of Wisconsin Investment Board lifted its position in shares of AMAG Pharmaceuticals by 34.6% during the second quarter. State of Wisconsin Investment Board now owns 35,000 shares of the specialty pharmaceutical company’s stock worth $682,000 after purchasing an additional 9,000 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of AMAG Pharmaceuticals by 6.2% during the second quarter. Renaissance Technologies LLC now owns 1,641,100 shares of the specialty pharmaceutical company’s stock worth $32,001,000 after purchasing an additional 96,300 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of AMAG Pharmaceuticals by 13.7% during the second quarter. Russell Investments Group Ltd. now owns 1,170,332 shares of the specialty pharmaceutical company’s stock worth $22,878,000 after purchasing an additional 140,741 shares in the last quarter. Sei Investments Co. lifted its position in shares of AMAG Pharmaceuticals by 1,695.3% during the second quarter. Sei Investments Co. now owns 506,429 shares of the specialty pharmaceutical company’s stock worth $9,876,000 after purchasing an additional 478,220 shares in the last quarter. Finally, Employees Retirement System of Texas lifted its position in shares of AMAG Pharmaceuticals by 13.6% during the second quarter. Employees Retirement System of Texas now owns 75,000 shares of the specialty pharmaceutical company’s stock worth $1,463,000 after purchasing an additional 9,000 shares in the last quarter.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Recommended Story: What is the Dividend Aristocrat Index?

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply